We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Bristol-Myers Squibb presented results from several clinical trials of its PD-L1 immunotherapy, Opdivo, including more detailed data from a Phase III trial that failed to show benefits as a first-line monotherapy in advanced non-small cell lung cancer. Read More
Pfizer presented results from a global Phase III study of Sutent as an adjuvant therapy following surgery for renal cell carcinoma, showing that it extended disease-free survival by more than one year in patients at high risk for recurrence. Read More
The United Nations High-Level Panel on Access to Medicine is proposing that governments rely on compulsory licenses to improve patient access to medicines in a highly anticipated report that has been met with dismay from industry. Read More
Two Phase III trials presented at the annual congress of the European Society for Medical Oncology showed advancements in first-line treatments for post-menopausal women with breast cancer. Read More
Merck presented multiple studies over the weekend demonstrating positive results in metastatic non-small cell lung cancer with its Keytruda immunotherapy. Read More
Over 90 percent of clinical trials evaluating targeted cancer therapies or immunotherapies fell short in reporting adverse events in their publications — specifically in reporting recurrent or late toxicities, and detailing the duration of adverse events — according to researchers who studied 81 trials related to FDA-approved solid tumor treatments. Read More